DRREDDY Quarterly Results Analysis
Earnings Analysis Dashboard – DRREDDY
Structured AI analysis of company financial results designed to help traders and investors quickly understand key performance trends.
Type of Announcement
The announcement details the financial performance of Dr. Reddy's Laboratories for the quarter ending June 30, 2026. It includes consolidated financial results, such as revenue, net profit, and earnings per share, along with major corporate appointments and other strategic updates.
Revenue
₹8070.5 Crs.
▲ +7.4% QoQ
Net Profit
₹434.8 Crs.
▲ +97% QoQ
EBITDA Margin
12.5%
▼ Declining
Key Financial Numbers (Quarter)
| Metric |
Current Quarter (Jun 2026) |
Previous Quarter (Mar 2026) |
Same Quarter Last Year (Jun 2025) |
| Revenue (₹ Crs.) |
8070.5 |
7516.2 |
8545.2 |
| Net Profit (₹ Crs.) |
434.8 |
220.5 |
1409.6 |
| EPS |
5.32 |
2.64 |
17.04 |
| EBITDA Margin (%) |
12.5% |
13.0% |
26.7% |
What EPS Means
EPS (Earnings Per Share) shows how much profit a company generates for each share.
Higher EPS usually indicates stronger profitability and better earnings power for shareholders.
What EBITDA Margin Means
EBITDA Margin measures operating profitability before interest, tax, depreciation and amortization.
A higher margin suggests the company is generating stronger operating profits from its revenue.
Revenue Trend
Jun 2026
₹8070.5 Crs.
Mar 2026
₹7516.2 Crs.
Jun 2025
₹8545.2 Crs.
Profit Trend
Jun 2026
₹434.8 Crs.
Mar 2026
₹220.5 Crs.
Jun 2025
₹1409.6 Crs.
Quick Interpretation
- QoQ revenue trend: Strong recovery (+7.4%)
- YoY revenue trend: Down sharply (-5.6%)
- QoQ net profit trend: Significant improvement (+97%)
- YoY net profit trend: Significant decrease (-69%)
Major Corporate Events
- Appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics.
- First-to-market launch of Bosutinib Tablets in the United States.
- Launch of generic semaglutide injection in Canada and tablets in India.
- Agreement with Innoviva Speciality Therapeutics.
Trading Signals
- Positive Factors: Strong growth in emerging markets, efficient cost management.
- Negative Factors: Decline in North America sales, impact from semaglutide API issues.
Overall Sentiment
Neutral
Disclaimer
This report has been analysed and generated using AI based on publicly available corporate announcements and financial disclosures published by the company on NSE INDIA Website.
We are not registered with SEBI as an investment advisor or research analyst. This report is provided strictly for informational and educational purposes only.
Investors should not treat this analysis as financial advice, stock recommendation, or investment guidance. Always conduct your own research or consult a SEBI-registered financial advisor before making investment decisions.
The platform does not guarantee accuracy, completeness, or timeliness of the extracted information.